Methods for evaluating the ability to metabolize...

Details Methods for evaluating the ability to metabolize... Methods for evaluating the ability to metabolize...

2005-08-16

2005-08-16

Johannsen, Diana B. (Department: 1634)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S019000, C435S091200, C536S023200, C536S023500, C536S024310, C536S024330

Reexamination Certificate

active

06929912

ABSTRACT:
Methods for detecting variant genes having a polymorphism associated with reduced metabolism of a substrate selected from the group consisting of a CYP3A4 substrate, a CYP3A5 substrate and a GSTM1 substrate in an individual are disclosed. The methods are genotyping methods to identify specific polymorphisms which have been found to be associated with reduced metabolism of chemotherapeutic agents, such as cyclophosphamide and BCNU. Also disclosed are novel polymorphic nucleic acid molecules useful in the methods of the invention.

REFERENCES:
patent: 5413915 (1995-05-01), Case et al.
patent: 5420027 (1995-05-01), Fisher et al.
patent: 5445934 (1995-08-01), Fodor et al.
patent: 5478723 (1995-12-01), Parkinson et al.
patent: 5506131 (1996-04-01), Harris et al.
patent: 5660986 (1997-08-01), Harris et al.
patent: 6174684 (2001-01-01), Rebbeck et al.
patent: 6183963 (2001-02-01), Sinnett et al.
patent: 92/19647 (1992-11-01), None
patent: WO 93/18178 (1993-09-01), None
patent: 95/35505 (1995-12-01), None
patent: WO 99/13106 (1999-03-01), None
patent: WO 00/39332 (2000-07-01), None
Petros, W. et al. Associations between variants in several drug metabolism genes and chemotherapy pharmacokinetics or clinical response. Proceedings of the American Association for Cancer Research Annual Meeting 42:266 (Mar. 2001).
Van Schaik, R. et al. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch caucasians. Clinical Chemistry 46(11):1834-1836 (2000).
Ambrosone, C. et al. Polymorphisms in glutathione S-transferases (GSTM-1 and GGTT1) and survival after treatment for breast cancer. Cancer Research 61:7130-7135 (Oct. 2001).
Felix et al., “Association of CYP3A4 genotype with treatment-related leukemia”;Proc. Natl. Acad. Sci. USA;vol. 95, 1998, pps. 13176-81.
Howells et al., “Association of Glutathione S-Transferase GSTM1 and GSTT1 Null Genotypes with Clinical Outcome in Epithelial Ovarian Cancer”;Clinical Cancer Research;vol. 4; 1998, pps. 2439-45.
Jungnellus, et al., “Simliar Toxic Effect of 1,3-BIS(2-Chloroethyl-1-Nitrosourea on Lymphocytes from Human Subjects Differing in the Expression of Glutathione Transferase M1-1”;Biochemical Pharmacology;vol. 47:10; 1994, pps. 1777-80.
Klrchea et al., “MGMT-and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas”;Clinical Neuropathology;vol. 18:1; 1999, pps. 1-8.
Lizard-Nacol et al., “Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer”;Breast Cancer Res.;vol. 1:1; 1999, pps. 81-87.
Nakamura et al., “Apparent Low Frequency of Sequence Variability within the Proximal Promoter Region of the Cytochrome P450 (CYP) 3A5 Gene in Established Cell Lines from Japanese Individuals”;Biol. Pharm. Bull.;vol. 24:8; 2001, pps. 954-57.
Brian et al.,Biochemistry,29: 11280-11292 (1990).
Carter et al.,Biochem.,197(2):301-308 (1995).
Delahunty et al.,Am. J. Hum. Genet.,58: 1239-1246 (1996).
DeRisi et al.,Nature Genetics,14: 457-460 (1996).
Golovieve et al.,Am. J. Hum. Genet.,59: 570-579 (1996).
Gonzalez et al., GenBank Accession No. M18907, Jun. 1989.
Hacia et al.,Nature Genetics,14: 441-447 (1996).
Hashimoto et al.,Eur. J. Biochem., 218: 585-595 (1993).
Hashimoto et al., GenBank Accession No. D11131, Jan. 1994.
Hiller et al., GenBank Accession No. H21215 (1995).
Jounaidi et al., GenBank Accession No. S74700, Apr. 1995.
Kawagish, GenBank Accession No. X59297 (1991).
Lewis et al.,Toxicology,125: 31-44 (1998).
Lockhart et al.,Nature Biotechnology,14: 1675-1680 (1996).
Lown et al.,J. Clin. Invest. The American Society for Clinical Investigation, Inc.,99(10): 2545-2553 (1997).
Mansfield et al.,Genomics,24: 225-233 (1994).
Marra, et al., GenBank Accession No. W35854 (1996).
Saiki et al.,Science,239: 441-532 (1988).
Sambrook et al., Molecular Cloning, A Laboratory Manual, 2ndEdition, Cold Spring Harbor Laboratory Press, 14.2-14.35 (1989).
Schuetz et al.,Molecular Pharmacology,49: 311-318 (1996).
Sulston, GenBank Accession No. Z73358 (1996).
Underhill et al.,Proc. Natl. Acad. Sci. USA,93: 196-200 (1996).
Waye et al., GenBank Accession No. R41114 (1995).
Waye et al., Protein Engineering 8 (Suppl): 90 (Miami Winter Bio Technology Symp. Proc.) 1995.
Wilson et al., GenBank Accession No. U-46669 (1996).
Wilson et al.,Nature,368: 32-38 (1994).
Yamazaki et al.,Archives of Biochemistry and Biophysics,342(2): 329-337 (1997).
Ziegle et al.,Genomics,14: 1026-1031 (1992).
Aoyama et al.,The Journal of Biological Chemistry,264(18): 10388-10395 (1989).
Aoyama et al., GenBank Accession No. J04813 (1993).
Aoyama et al., GenBank Accession No. NM000777 (2000).
Ball et al.,Clinical Pharmacology&Therapeutics,66(3): 288-294 (1999).
Bork et al.,The Journal of Biological Chemistry,264(2): 910-919 (1989).
Brockmoller et al.,Toxicol Lett,102-103:173-83 (1998).
Domanski et al.,Molecular Pharmacology,59:386-392 (2001).
Dunning et al.,Cancer Epidemiology, Biomarkers&Prevention,8: 843-854 (1999).
Finta et al.,Gene,260: 13-23 (2000).
Fryer et al.,IARC Sci Publ,148: 303-322 (1999).
Gellner et al., GenBank Accession No. AF280107 (2000).
Gonzalez et al.,DNA,7(2): 79-86 (1988).
Gonzalez et al., GenBank Accession No. P08684 (1988).
Hashimoto et al.,Eur. J. Biochem.,218: 585-595 (1993).
Hashimoto et al., GenBank Accession No. D11131 (2000).
Helzlsouer et al.,Journal of the National Cancer Institute,90: 512-518 (1998).
Hengstler et al.,Recent Results Cancer Res.,154: 47-85 (1998).
Hilbert et al.,The Journal of Biological Chemistry,272(10): 6733-6740 (1997).
Hsieh et al., GenBank Accession No. AF209389 (1999).
Jounaidi, Y., GenBank Accession No. X90579 (1996).
Jounaidi et al.,Biochemical and Biophysical Research Communications,205(3): 1741-1747 (1994).
NCBI Annotation Project, GenBank Accession No. XM_011598 (2001).
Peyronneau et al.,Eur. J. Biochem,218: 355-361 (1993).
Sachse et al.,Am. J. Hum. Genet.,60: 284-295 (1997).
Schuetz et al.,Archives of Biochemistry and Biophysics,274(2): 355-365 (1989).
Schuetz, GenBank Accession No. L26985 (1994).
Schuetz et al., GenBank Accession No. L35912 (1996).
Sherif et al.,Cancer Letters,107: 229-233 (1996).
Xu et al.,The Journal of Biological Chemistry,273(6): 3517-3527 (1998).
Skolnick,J. Am. Med. Assn.,275(8): 581-2 (1996).
Strange et al.,IARC Sci. Publ.,148: 231-249 (1999).
Strange et al.,Chem. Biol. Interact,24(111-112): 351-364 (1998).
Sulston et al., GenBank Accession No. AC005020 (2000).
Watanabe, M.,Toxicol. Lett,28(102-103): 167-171 (1998).
Westlind et al.,Biochemical and Biophysical Research Communications,259: 201-205 (1999).
Kuehl, Peter et al., “Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression,”Nature Genetics,p. 383-391, (Apr. 2001).

Affiliated with

Also associated with

Rating

Methods for evaluating the ability to metabolize... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for evaluating the ability to metabolize..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for evaluating the ability to metabolize... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3499282